Evaluation of Biomarkers of COPD Exacerbation
Evaluation of Biomarkers of COPD Exacerbation
Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive
 pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to
 ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by
 binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA
 and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in
 patients with stable COPD and AE-COPD.
Patient enrolment and data aquisition is to be carried out on a prospective basis. It is
 planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will
 undergo blood sampling inlcuding SAA and Lipoxin A4.
Inclusion Criteria:

 -  Patients with COPD GOLD 3-4 confirmed by anamnesis and pulmonary function test

 -  Patient has provided written informed consent

 Exclusion Criteria:

 -  other reasons for worsening of symptoms (cough, dyspnea): e.g. pneumothorax,
 pneumonia, pulmonary embolism, myocardial infarction.

 -  malignant disease